Environmental

NRXP appears to have limited disclosed environmental intensity data, which constrains peer benchmarking and leaves its relative footprint unclear versus biotech peers.

The company’s R&D-heavy model typically implies lower direct operational emissions than manufacturing peers, but the absence of verified disclosures weakens confidence in that advantage.

No material environmental controversies or regulatory breaches were provided, which supports a neutral-to-slightly-better position relative to peers with more visible environmental liabilities.

Because environmental impacts in this sector are mainly indirect and disclosure-driven, NRXP’s positioning is broadly in line with smaller clinical-stage peers rather than clearly leading.

Social

NRXP’s high R&D intensity suggests reliance on specialized scientific talent, which can support workforce quality but also increases execution risk versus larger peers with deeper benches.

Stock-based compensation at 12.9% of revenue indicates meaningful equity reliance, which can align employees but may dilute retention quality if peer packages are stronger.

No Tier 1 evidence of major product-safety, labor, or community controversies was provided, leaving social risk moderate rather than structurally weak versus peers.

As a small biotech, NRXP likely faces similar patient, trial, and access expectations as peers, but the available data do not show a clear social advantage.

Governance

NRXP’s negative debt-to-equity ratio suggests a capital structure that is difficult to interpret cleanly, which can reduce governance transparency versus more straightforward peers.

Stock-based compensation remains material at 12.9% of revenue, implying dilution sensitivity and potentially weaker capital-allocation discipline than better-capitalized peers.

The absence of provided filing-based governance details on board independence, controls, or shareholder protections limits evidence of strong governance relative to peers.

Overall governance appears constrained by limited disclosure and capital-structure complexity, leaving NRXP below stronger-reporting peers but not indicating a severe failure.

Overall Score

NRXP’s ESG profile is broadly average for a small clinical-stage biotech, with limited disclosure and capital-structure complexity offsetting the absence of major controversies.

Score Driver: Limited ESG Disclosure And Governance Transparency Relative To Peers.